PSTV

Company Overview — What Does PLUS THERAPEUTICS, INC. Do?

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. PLUS THERAPEUTICS, INC. (PSTV) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Marc H. Hedrick and employs approximately 20 people, headquartered in AUSTIN , Texas. With a market capitalization of $1M, PSTV is one of the notable companies in the Healthcare sector.

PLUS THERAPEUTICS, INC. (PSTV) Stock Rating — Reduce (April 2026)

As of April 2026, PLUS THERAPEUTICS, INC. receives a Reduce rating with a composite score of 26.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PSTV ranks #3,490 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PLUS THERAPEUTICS, INC. ranks #543 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PSTV Stock Price and 52-Week Range

PLUS THERAPEUTICS, INC. (PSTV) currently trades at $4.82. The stock gained $0.90 (23.0%) in the most recent trading session. The 52-week high for PSTV is $2.08, which means the stock is currently trading 131.7% from its annual peak. The 52-week low is $0.16, putting the stock 2849.8% above its annual trough. Recent trading volume was 1.3M shares, reflecting moderate market activity.

Is PSTV Overvalued or Undervalued? — Valuation Analysis

PLUS THERAPEUTICS, INC. (PSTV) carries a value factor score of 6/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.01x, versus the sector average of 2.75x. The price-to-sales ratio is 3.78x, compared to 1.66x for the average Healthcare stock.

At current multiples, PLUS THERAPEUTICS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

PLUS THERAPEUTICS, INC. Profitability — ROE, Margins, and Quality Score

PLUS THERAPEUTICS, INC. (PSTV) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -489.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -119.7% versus the sector average of -33.1%.

On a margin basis, PLUS THERAPEUTICS, INC. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -256.6% (sector: -66.1%). Net profit margin stands at -446.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 9.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PSTV Debt, Balance Sheet, and Financial Health

PLUS THERAPEUTICS, INC. has a debt-to-equity ratio of 309.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.23x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $13M.

PSTV has a beta of -1.40, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for PLUS THERAPEUTICS, INC. is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

PLUS THERAPEUTICS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, PLUS THERAPEUTICS, INC. reported revenue of $5M and earnings per share (EPS) of $-0.29. Net income for the quarter was $-20M. Gross margin was 100.0%. Operating income came in at $-13M.

In FY 2025, PLUS THERAPEUTICS, INC. reported revenue of $5M and earnings per share (EPS) of $-0.29. Net income for the quarter was $-22M. Revenue grew -10.5% year-over-year compared to FY 2024. Operating income came in at $-15M.

In Q3 2025, PLUS THERAPEUTICS, INC. reported revenue of $1M and earnings per share (EPS) of $-0.04. Net income for the quarter was $-4M. Revenue grew -4.1% year-over-year compared to Q3 2024. Operating income came in at $-4M.

In Q2 2025, PLUS THERAPEUTICS, INC. reported revenue of $1M and earnings per share (EPS) of $0.02. Net income for the quarter was $5M. Revenue grew 8.7% year-over-year compared to Q2 2024. Operating income came in at $-2M.

Over the past 8 quarters, PLUS THERAPEUTICS, INC. has demonstrated a growth trajectory, with revenue expanding from $1M to $5M. Investors analyzing PSTV stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PSTV Dividend Yield and Income Analysis

PLUS THERAPEUTICS, INC. (PSTV) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PSTV Momentum and Technical Analysis Profile

PLUS THERAPEUTICS, INC. (PSTV) has a momentum factor score of 42/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 29/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

PSTV vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, PLUS THERAPEUTICS, INC. (PSTV) ranks #543 out of 838 stocks based on the Blank Capital composite score. This places PSTV in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PSTV against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PSTV vs S&P 500 (SPY) comparison to assess how PLUS THERAPEUTICS, INC. stacks up against the broader market across all factor dimensions.

PSTV Next Earnings Date

No upcoming earnings date has been announced for PLUS THERAPEUTICS, INC. (PSTV) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PSTV? — Investment Thesis Summary

The quantitative profile for PLUS THERAPEUTICS, INC. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 6/100 indicates premium valuation. High volatility (stability score 27/100) increases portfolio risk.

In summary, PLUS THERAPEUTICS, INC. (PSTV) earns a Reduce rating with a composite score of 26.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PSTV stock.

Related Resources for PSTV Investors

Explore more research and tools: PSTV vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PSTV head-to-head with peers: PSTV vs AZN, PSTV vs SLGL, PSTV vs VMD.